Hungary: A New Model of Care
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Patent Ltd. was founded in 1989.
Our company mainly fabricates custom made stainless steel vessels for pharmaceutical, food and chemical industry. Beside that we have a serial production of special stainless steel structures for the energetics. To fulfill the needs of the the market, we are continuously improving our fabrication infrastructure.
Of course we are having the essential licenses for pressure vessel fabrications not only for Hungarian but also for the EU market. Our company has been qualified for the production of welded structures, pressure tanks and storage tanks of hazardous substances according to the requirements of DIN EN ISO 3834-2 / MSZ EN ISO 3834-2, AD 2000 Merkblatt HPO. We can fabricate according the requirements of 97/23/EK directive’s G; B1+F és B+F modul depending on the classification of the equipment. (PED)
We have a license to fabricate storage tanks for hazardous liquids and melts according to 11/1994 (III. 25.) IKM departmental order, and EN 15085 Railways Manufacturer’s Certificate.
And to be able to coordinate these special requirements we have established and introduced the MSZ EN ISO 9001-2008 quality assurance system.
Patent has relevant domestic and international experience, we are supplying a complex service from the design till the FAT (or till IQ, OQ). Depending the needs of our client the documentation we can supply in English, German or in Russian language.
Contact
2700 Cegléd, Bürgeházdűlő
Mail address: 2700 Cegléd, Pf.261
+36 30/439-0002
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…
While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary…
Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable…
Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in…
The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges…
LEO Pharma Hungary’s Andrea Bondár demonstrates the significance of adopting non-traditional methods of promotional activities, and defines how a true intent on understanding the psyche of patients suffering from chronic…
Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into…
Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation…
Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges…
The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic…
See our Cookie Privacy Policy Here
